Trevena (TRVN)
(Delayed Data from NSDQ)
$0.39 USD
-0.01 (-2.74%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.39 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Trevena, Inc. [TRVN]
Reports for Purchase
Showing records 101 - 114 ( 114 total )
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
TRV130?s Ph2b Results Increase Approval Odds; Safety Profile Impressive
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Profile of TRV130 Confirmed as a Differentiated Drug; Reiterate OUTPERFORM and Raising PT to $20
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 31
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Finishes Enrollment of TRV130 Phase IIb Study with Details on Interim Look; Reiterate OUTPERFORM and $15 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Ahead Of Our Estimates. TRV130''s Phase 2b Is Enrolled; Data In Sept.
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
A "Real World" Look - TRV130 Data Preview; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Initiation: We Recommend Buying Ahead of TRV130''s Phase 2b 3Q15 Results
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Earnings in Line With TRV130 Data on the Horizon
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage of Trevena with OUTPERFORM; Novel Platform Lays Path to Large Markets
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H